胃肠激素对肥胖的影响及抗肥胖药物研究进展  

The Impact of Gastrointestinal Hormones on Obesity and Advances in Anti-Obesity Drug Research

作　　者：安输[1,2] 白娅 徐天瑞 AN Shu;BAI Ya;XU Tianrui(Faculty of Life Science and Technology,Kunming University of Science and Technology,Kunming 650500,China;Key Laboratory of Targeted Drug Screening and Utilization in Yunnan Province,Kunming 650500,China)

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650500 [2]云南省高校靶点药物筛选与利用重点实验室,云南昆明650500

出　　处：《昆明理工大学学报（自然科学版）》2024年第3期218-228,共11页Journal of Kunming University of Science and Technology(Natural Science)

基　　金：国家自然科学基金项目(82160564);云南省重大科技项目(202202AG050008).

摘　　要：在过去30年中,肥胖已成为全球关注的主要公共卫生问题,其发病率显著上升,全球患病人数已达10.38亿.肥胖不仅增加了2型糖尿病、心血管疾病及某些恶性肿瘤的患病风险,还带来了严重的经济和社会负担.作为一种异质性疾病,肥胖的发生与多种因素相关,其中摄食过多和能量消耗过少是主要原因.近年来,研究发现胃肠激素在调节进食和能量代谢中起着关键作用.综述了多种胃肠激素如胰高血糖素样肽-1(GLP-1)、葡萄糖依赖性促胰岛素多肽(GIP)和饥饿素(Ghrelin)等在肥胖中的作用机制,并重点介绍了基于这些激素抗肥胖药物的研发进展,特别是GLP-1受体激动剂已显示出显著的临床疗效,成为治疗肥胖的重要药物.通过总结当前的研究成果和临床试验数据,旨在为未来的肥胖治疗提供新的思路和方向.Over the past 30 years,obesity has become a major global public health concern,with its incidence rising significantly.The global population affected by obesity has reached 1.038 billion.Obesity not only increases the risk of type 2 diabetes,cardiovascular diseases,and certain malignancies but also imposes severe economic and social burdens.As a heterogeneous disease,obesity is associated with multiple factors,primarily excessive food intake and insufficient energy expenditure.Recent studies have discovered that gastrointestinal hormones play a crucial role in regulating food intake and energy metabolism.This review summarizes the mechanisms by which various gastrointestinal hormones,such as glucagon-like peptide-1(GLP-1),glucose-dependent insulinotropic polypeptide(GIP),and ghrelin,influence obesity.It also highlights the progress in developing anti-obesity drugs targeting these hormone receptors.Notably,GLP-1 receptor agonists have demonstrated significant clinical efficacy,becoming blockbuster drugs for obesity treatment.By summarizing current research findings and clinical trial data,this paper aims to provide new insights and directions for future obesity treatment.

关 键 词：胃肠激素 肥胖 抗肥胖药物 胰高血糖素样肽-1受体 胰高血糖素受体 

分 类 号：R589.2[医药卫生—内分泌]